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A rapid and simple high-performance liquid chromatographic
method for the analysis of 1,3-dihydroxy-2-methylxanthone
(DHMXAN) in biodegradable poly(D,L-lactide-co-glycolide) (PLGA)
nanosphere and nanocapsule formulations is developed and
validated. The method does not require any complex sample
extraction procedure. Chromatographic separation is made with a
reversed-phase C18 column, using methanol–water (90:10, v/v)
containing 1% (v/v) acetic acid as a mobile phase at a flow rate of
1 mL/min. Identification is made by UV detection at 237 nm. The
isocratic system operates at ambient temperature and requires 7.5
min of chromatographic time. The developed method is statistically
validated according to ICH guidelines and USP 29 for its specificity,
linearity, accuracy, and precision. The assay method proposed in
this study is specific for DHMXAN in the presence of nanosphere
and nanocapsule excipients. Diode-array analyses confirm the
purity of DHMXAN peak in stress conditions (> 99.0%). The
method is shown to be linear (r ≥ 0.999) over the concentration
range of 0.25–3.0 µg/mL. Recovery ranges from 99.0% to 102.7%
(RSD: 1.49%) and from 98.3% to 101.6% (RSD: 1.07%) for
nanospheres and nanocapsules, respectively. Repeatability (intra-
assay precision) and intermediate precision is acceptable with RSD
values ranging from 0.6% to 1.9% and from 0.3% to 2.0%,
respectively. The method is shown to be suitable for the evaluation
of DHMXAN content entrapped in PLGA nanoparticles.
Introduction
Xanthones represent a large group of heterocyclic com-
pounds, including natural, semisynthetic, and totally synthetic
structures based on the dibenzo-γ-pyrone nucleus (1,2).
Xanthonic derivatives constitute a group of compounds with a
broad spectrum of biological activities (e.g., antitumor, hepato-
protection, and modulation of enzyme protein Kinase C) (3).
1,3-Dihydroxy-2-methylxanthone (DHMXAN) (Figure 1) is a syn-
thetic derivative that showed the highest inhibitory effect on the
growth ofMCF-7 human breast cancer cell line among a set of 27
tested xanthones (4).
Poor aqueous solubility of many xanthonic derivatives is a
major obstacle for the assessment of pharmacological activity of
these compounds and for their use in the therapy. Besides the
difficulty on the administration of water-insoluble drug sub-
stances, this characteristic is often associated with poor bioavail-
ability (5). Technology for micro- and nano-particulate systems
has emerged as an alternative to overcome the difficulty of
administration of poorly water-soluble compounds (6). The effi-
ciency of this approach was successfully proven for different
drugs (7–9). Nanoparticles are polymeric drug carriers of
nanometer size (10). According to the preparation process either
nanospheres or nanocapsules can be obtained. Nanospheres are
matrix-type systems composed of an entanglement of oligomer
or polymer units, in which the drug is dispersed throughout the
polymer matrix. Nanocapsules are reservoir-type systems where
the drug is confined to a cavity surrounded by a polymeric mem-
brane (11,12). Poly(DL-lactide-co-glycolide) (PLGA) is an exten-
sively studied polymer for pharmaceutical use due to its
biocompatibility and biodegradability properties (13). Besides
the improvement of delivery of water-insoluble drugs, nanopar-
ticles have afforded several advantages for different drugs, such
as reduce drug-associated adverse effects (11), protect the com-
pound from inactivation before reaching its site of action (14),
and increase the intracellular penetration (15). In a previous
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Figure 1. Chemical structure of 1,3-dihydroxy-2-methylxanthone
(DHMXAN).
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work, we have demonstrated that the encapsulation of xanthone
and 3-methoxyxanthone in PLGA nanocapsules afforded a
remarkable improvement of the inhibitory effect on the produc-
tion of NO by the murine macrophage cell line J774 (16).
Through the incorporation of DHMXAN in nanoparticles,
aqueous dispersions with concentrations higher than the max-
imum aqueous solubility of this compound may be achieved for
administration. Moreover, this approach may allow different
ways of administration and may afford its in vivo protection and
targeting.
In order to test the usefulness of PLGA nanoparticles as poten-
tial carriers for xanthones, we routinely carry out in vitro studies
with these colloidal formulations containing different xanthonic
compounds. To facilitate the pharmaceutical development of
xanthone-containing nanoparticle formulations an analytical
method for the detection and quantitation of the analyte is nec-
essary to guarantee the reliability of the results. The aim of the
present work was to develop and validate a specific and simple
high-performance liquid chromatographicmethod for the quan-
titative analysis of DHMXAN, which was entrapped in PLGA
nanoparticles for the first time. The procedures and parameters
used for validation of the analytical method were those described
in the International Conference on Harmonization (ICH) guide-
lines (17,18), which are similar to the ones established by the
United States Pharmacopoeia 29 (USP 29) (19).
Experimental
Reagents and chemicals
PLGA 50:50 (MW 50,000–75,000), Pluronic F-68, glucose, and
soybean lecithin (40% purity by TLC) were purchased from
Sigma-Aldrich Química (Sintra, Portugal). DHMXAN (purity >
99.0% by HPLC; m.p. 141–142°C) was synthesised in our labora-
tory according to themethod already described (20).Myritol 318
was kindly supplied by Henkel (Lisboa, Portugal). HPLC-grade
methanol and acetonitrile were obtained from Merck KGaA
(Darmstadt, Germany). HPLC grade water was obtained by a
MilliQ system (Millipore, Lisboa, Portugal). Other chemicals
were of analytical grade.
Nanoparticle preparation and characterization
Nanospheres containing DHMXAN were prepared by the sol-
vent displacement technique (21). Briefly, a solution of PLGA (50
mg) and DHMXAN (0.75 mg) in a mixture of acetone (9.5 mL)
and methylene chloride (0.5 mL) was poured into 10 mL of an
aqueous solution of Pluronic F-68 0.25 % (w/v), under moderate
stirring, leading to the formation of nanospheres. Then, acetone
was removed under vacuum and the colloidal dispersion of
nanospheres was concentrated to 5 mL by evaporation under
reduced pressure. DHMXAN crystals were removed by filtration
(0.8 µmmixed cellulose esters membrane filters fromMillipore).
Non-incorporated DHMXAN was removed by centrifugation at
2000 × g for 2 h (Heraeus Sepatech Labofuge Ae centrifuge,
Osterode/Harz, Germany) after solubilization of a certain
amount of glucose for achieving a 5% (w/v) concentration. The
supernatant was discarded and the pellet containing the
nanospheres was redispersed in water to complete the initial
volume of nanosphere dispersion submitted to centrifugation.
Empty nanospheres were prepared according to the same proce-
dure but omitting the xanthone in the organic phase.
Nanocapsules containing DHMXAN were prepared by the
interfacial polymer deposition method described by Fessi et al.
(22). Briefly, 50 mg of polymer and 100 mg of soybean lecithin
were dissolved in 10 mL of acetone. DHMXAN (2.5 mg) was dis-
solved in 0.6 mL of Myritol 318 and the obtained solution was
added to the acetone solution. The final solution was poured into
20 mL of an aqueous solution of Pluronic F-68 0.5% (w/v) under
moderate stirring, leading to the formation of nanocapsules.
Then, acetone was removed under vacuum and the colloidal dis-
persion of nanocapsules was concentrated to 5 mL by evapora-
tion under reduced pressure. Non-encapsulated DHMXAN was
separated by ultrafiltration/centrifugation using centrifugal
filter devices Centricon YM-50 (Millipore, Lisboa, Portugal) at
4000 × g for 2 h (Beckman UL-80 ultracentrifuge, Albertville,
MN). Empty nanocapsules were prepared according to the same
procedure but omitting the DHMXAN in the organic phase.
Particle size and zeta potential of nanoparticles were assessed
by photon correlation spectroscopy (PCS) and by laser Doppler
anemometry (LDA), respectively using a Zetasizer 5000 appa-
ratus (Malvern Instruments, Malvern, UK).
Instrumental and chromatographic conditions
The HPLC analysis was performed with a JASCO liquid chro-
matograph (Japan Spectroscopic, Ltd, Tokyo, Japan) equipped
with a JASCO 880-PU pump and a JASCO 875-UV spectrophoto-
metric detector. The separation was carried out on a 250 × 4.6
mm i.d. Nucleosil C18 column (5 µm) (Macherey-Nagel, Düren,
Germany). LC analysis was performed by isocratic elution. The
mobile phase composition was 90:10 (v/v) methanol–water con-
taining 1% (v/v) acetic acid and the flow rate was set at
1 mL/min. The injected volume was 20 µL, and the detection
wavelength was set at 237 nm. CWS 1.7 software (DataApex Ltd,
Prague, Czech Republic) managed chromatographic data.
Analysis of samples of DHMXAN subjected to thermal, acid,
and alkaline stress conditions was also performed byHPLC using
a different system equipped with an on-line diode-array detector
(DAD). A Spectra System liquid chromatograph equipped with a
Series II Digital pump (Science Marketing International,
Gloucester, UK) with diode-array UV6000LP detector (Thermo
Separation Products, Waltham, MA) was used. Samples were
chromatographed using the same procedure described above,
including the column, injected volume and detection wave-
length. Chromquest for Windows NT software (ThermoQuest,
Waltham, MA) managed chromatographic data.
Preparation of sample solutions for determination of
DHMXAN in nanoparticles
Sample solutions were prepared by dissolving an aliquot of
DHMXAN nanosphere or nanocapsule dispersion in acetonitrile
(corresponding to a dilution of 1/50 and 1/500, respectively) and
subjected to HPLC analysis. Considering 100% of entrapment of
DHMXAN in nanoparticles, the obtained sample solutions had a
maximum theoretical concentration (MTC) of 1.0 µg/mL and
3.0 µg/mL for nanocapsules and nanoparticles, respectively.
All analyses were performed in triplicate and the
mean results (± SD) are reported.
Encapsulation efficiency (EE) was calculated
as follows:
EE (%) = A/B × 100
where A is the drug concentration (µg/mL) in
the nanoparticle dispersions and B is the theo-
retical drug concentration (µg/mL).
Preparation of DHMXAN standard solutions
Stock standard solutions of DHMXAN (20
µg/mL) were prepared in acetonitrile. Standard
solutions were obtained by dilution of a freshly
prepared stock standard solution with acetoni-
trile to give seven different concentrations over
the range of interest (0.25 to 3.0 µg/mL).
Method validation
Specificity
The specificity of the analytical method was
determined either in samples of DHMXAN sub-
mitted to thermal, acidic, and alkaline stress
conditions or in samples containing the xan-
thonic compound and nanoparticle excipients
(i.e., spiked with empty nanoparticles). For the evaluation of
thermal degradation, a known amount (1 mg) of the compound
was placed in an oven at 120°C for 2 h. Afterwards, the sample
was dissolved in methanol and subjected to the HPLC analysis.
For the evaluation of the DHMXAN degradation in acidic and
alkaline conditions, a known amount (1 mg) of the compound
was mixed with 25 mL of 1N HCl and with 1N NaOH. Following
36 h of stirring at room temperature, samples were filtered. The
pH of the alkaline solution was adjusted to 1.0 with 1NHCl. Both
solutions were submitted to extraction with chloroform. The
obtained organic solutions were evaporated until dryness and
the residues dissolved in methanol and subjected to HPLC anal-
ysis. Control samples (without DHMXAN) were also prepared
and assayed.
Linearity and range
Linearity of the method over the concentration range of
0.25–3.0 µg/mL was examined. This range corresponds to
8.5–100% and 25–300% of the MTC of DHMXAN in nanospheres
and nanocapsules, respectively. Linear regression analysis was
carried out by plotting peak area (y) versus analyte concentra-
tion (x). Calibration curve was constructed at seven concentra-
tion levels using the linear squares regression procedure. The
overall procedure was repeated three times on different days.
Accuracy
According to ICH guidelines (17,18) and USP 29 (19), the
accuracy of an analytical method expresses the closeness of
agreement between the value that is accepted either as a con-
ventional true value or an accepted reference value and the value
found. Accuracy is often calculated as percent recovery by the
assay of known, added amounts of analyte to the sample.
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Figure 2. Representative chromatograms obtained following injection of: (A) DHMXAN standard
solution (1.5 µg/mL), (B) DHMXAN subjected to thermal degradation (120°C, 2 h), (C) acid degrada-
tion (HCl 1N, 36 h) and (D) basic degradation (NaOH 1N, 36 h), (E) DHMXAN standard solutions (1
µg/mL) spiked with empty nanospheres, and (F) empty nanocapsules.
Figure 3. UV spectra of DHMXAN samples submitted to acid (A) and alkaline
(B) degradation conditions.
Accuracy should be assessed using a minimum of nine determi-
nations over a minimum of three concentration levels.
Accuracy was determined by spiking known amounts of
DHMXAN to aqueous dispersions of empty nanospheres or
nanocapsules in order to obtain concentrations of 0.5, 1.0, and
2.0 µg/mL (corresponding approximately to 17%, 33%, and 67%
of MTC in nanospheres) and of 0.25, 0.5, and 1.0 µg/mL (corre-
sponding approximately to 25%, 50%, and 100% of MTC in
nanocapsules).
Precision
Repeatability (intra-assay precision) of the chromatographic
method was determined by the analysis on the same day of seven
standard solutions of DHMXAN in the concentration range of
0.25–3.0 µg/mL (three replicates each). Intermediate precision
of the chromatographic method was determined by the analysis
of the same standard solutions on three different days.
The repeatability of the total analytical method was investi-
gated by performing six replicates samples of the same batch of
nanospheres and of nanocapsules containing DHMXAN.
Results and Discussion
Method development and optimization
The methanol–water (90:10, v/v) was initially evaluated as
mobile phase for the HPLC determination of DHMXAN based on
our previous experience with other xanthones (23).
Nevertheless, in this case, the use of this mobile phase resulted
in asymmetric and tailed peaks. In order to overcome peak
tailing, sample ionization was suppressed by adding 1% (v/v) of
acetic acid to the selected mobile phase (24). Therefore, a mobile
phase of 90:10 (v/v) methanol–water containing 1% (v/v) acetic
acid was selected. A flow rate of 1mL/min gave an optimal signal-
to-noise ratio and a reasonable separation time. Retention time
of DHMXANwas 5.3min, and the total time required for analysis
was 7.5 min. The maximum absorption of the compound in the
experimental conditions was found to be 237 nm, which was the
selected wavelength for the analysis.
Acetonitrile was used for preparation of sample solutions of
nanosphere and nanocapsule dispersions containing DHMXAN.
Different dilutions were evaluated in order to achieve a complete
dissolution of nanoparticle aqueous dispersions. Upon a 50- and
500-fold dilution of aliquots of nanosphere and nanocapsule dis-
persions, respectively, a complete disso-
lution was observed.
Method validation
Specificity
Figure 2A shows a representative chro-
matogram of a DHMXAN standard solu-
tion (1.5 µg/mL) with a retention time of
5.3 min. Another peak with a retention
time of approximately 2.5min, due to the
solvent front, was observed. Chro-
matograms corresponding to xanthone
samples subjected to stress treatment in
thermal, acidic, and alkaline conditions
are also shown in Figure 2 (2B, 2C, and
2D). No degradation was observed under
the studied temperature conditions
(Figure 2B). In acidic and alkaline condi-
tions, no interfering peaks with retention
times similar to the one of the DHMXAN
were observed.
The same samples were also analyzed
using an HPLC apparatus equipped with
an on-line diode-array detector (HPLC–
DAD). In samples submitted to acidic and
alkaline stress, additional peaks, besides
the one correspondent to DHMXAN,
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Table I. Summary of Standard Curve Results*
Concentration Average peak area response RSD
(µg/mL) (mV) (%)
0.25 35.28 4.44
0.5 73.13 4.28
0.6 81.87 4.20
1.0 142.79 3.22
1.5 206.42 4.37
2.0 285.31 2.51
3.0 427.04 1.75
* Y-intercept = –1.09 ± 4.56 and Slope = 142.3 ± 2.93, with confidence limits
(P = 0.05); correlation coefficient (r) = 0.99908; coefficient of determination
(R2) = 0.99816.
Table II. Results of Accuracy Determinations
Nanospheres Nanocapsules
Theoretical Experimental Theoretical Experimental
concentration concentration Recovery concentration concentration Recovery
(µg/mL) % MTC (µg/mL) (%) (µg/mL) % MTC (µg/mL) (%)
0.5 17 0.508 101.60 0.25 25 0.250 100.00
0.5 17 0.511 102.20 0.25 25 0.251 100.56
0.5 17 0.495 99.00 0.25 25 1.250 100.00
Mean recovery (%) 100.93 Mean recovery (%) 100.19
R.S.D. (%) 1.69 R.S.D. (%) 0.323
1.0 33 0.991 99.10 0.5 50 0.494 98.86
1.0 33 0.995 99.50 0.5 50 0.495 99.02
1.0 33 1.027 102.70 0.5 50 0.494 98.72
Mean recovery (%) 100.43 Mean recovery (%) 98.87
R.S.D. (%) 1.96 R.S.D. (%) 0.152
2.0 67 2.039 101.95 1.0 100 0.983 98.26
2.0 67 2.034 101.70 1.0 100 0.989 98.87
2.0 67 1.989 99.45 1.0 100 1.016 101.59
Mean recovery (%) 101.3 Mean recovery (%) 99.56
R.S.D. (%) 1.36 R.S.D. (%) 1.78
Overall mean recovery (%) 100.80 Overall mean recovery (%) 99.54
R.S.D. (%) 1.49 R.S.D. (%) 1.07
Journal of Chromatographic Science, Vol. 46, July 2008
476
were found (Figures 2C and 2D). The UV-spectra recorded for
these samples by the HPLC–DAD system are shown in Figure 3.
Regarding acidic samples (Figure 3A), the UV-spectrum of peak
no. 2 (tr = 7.04 min) clearly deviate from the DHMXAN spec-
trum, indicating modifications in the chromophore of the
molecule, probably due to an alteration of molecular structure
(e.g., the hydrogen bond disruption). The UV-spectrum of peak
no. 1 (tr = 4.68 min) was not representative, probably due to the
small amount of the formed product. Regarding alkaline samples
(Figure 3B), the UV-spectra of peaks no. 3 and no. 4 were also not
representative. Obtained results indicate a high resistance to
degradation of the DHMXAN under the tested alkaline condi-
tions.
The UV-spectra of the peak corresponding to xanthonic com-
pound remained identical after subjecting the samples to
thermal, acidic, and alkaline stress conditions. The peak purity
was, in all cases, higher than 99.0%. This indicates that there
were not degradation products co-eluting with DHMXAN and
demonstrates the stability-indicating capability of the analytical
method.
In order to evaluate the specificity of the method concerning
the presence of nanoparticle excipients (i.e., the potential inter-
ference of the excipients), a comparison of the results from the
analysis of DHMXAN standard solutions spiked with empty
nanospheres or nanocapsules with those correspondent to
DHMXAN standard solutions was carried out. Obtained chro-
matograms (Figures 2E and 2F) show the absence of any peak in
the region where xanthone elute, which indicates that the
method is specific concerning to nanoparticle excipients.
Linearity and range
The assay was linear with a relative standard deviation of 2.4%
in the response factors (area divided by concentration) in the
tested concentration range and correlation coefficients (r) ≥
0.999 and coefficients of determination (R2) > 0.9982 (i.e., over
99.82% of relationship between x and y) were found for all three
calibration curves (Table I).
Accuracy
Table II summarizes the accuracy results, expressed as percent
recovery and relative standard deviation (RSD). Recovery data
were within the range of 99.45–102.20% (RSD = 1.49%) and
98.26–101.59% (RSD = 1.07%) for nanospheres and nanocap-
sules, respectively. Overall mean recovery values were 100.80%
(n = 9) for nanospheres and 99.54% (n = 9) for nanocapsules.
Because the mean recovery results were within an acceptable ±
3% range, according to Segall et al. the method was deemed to
be accurate (25).
Precision
Tables III and IV summarize precision of the chromatographic
and of the total analytical method, respectively. Obtained RSD
values ranged from 0.6% to 1.9%. Results are greater than 2%,
indicating that both the chromatographic and the total analyt-
ical method show acceptable precision, in agreement with the
criteria proposed by Shabir (26).
Application of the developed method for the quantitation of
DHMXAN in nanoparticles
The analytical method is effective, fast, and meets all criteria
formethod validation and can be applied for the quantification of
DHMXAN encapsulated in different batches of nanoparticle for-
mulations. Figures 4A and 4B show representative chro-
matograms of nanospheres and nanocapsules containing
DHMXAN. None of these chromatograms show any interfering
peaks. Furthermore, peak purity was higher than 99%, indi-
cating that the preparation method did not produced degrada-
tion of xanthonic compound.
Table III. Results of Precision of the Chromatographic
Method
Repeatability (intra-assay precision)
Theoretical Mean experimental
concentration concentration
(µg/mL) (µg/mL) [n] SD RSD (%)
0.25 0.248 [3] 0.001 0.6
0.5 0.522 [3] 0.008 1.6
0.6 0.587 [3] 0.009 1.6
1.0 0.997 [3] 0.019 1.9
1.5 1.480 [3] 0.019 1.3
2.0 2.016 [3] 0.034 1.7
3.0 2.999 [3] 0.026 0.9
Intermediate precision (different days)
Theoretical Mean experimental
concentration concentration
(µg/mL) (µg/mL) [n] SD RSD (%)
0.25 0.246 [3] 0.003 1.2
0.5 0.508 [3] 0.010 2.0
0.6 0.574 [3] 0.011 1.9
1.0 1.000 [3] 0.009 0.9
1.5 1.476 [3] 0.005 0.3
2.0 2.018 [3] 0.029 1.5
3.0 2.996 [3] 0.057 1.9
Figure 4. Representative chromatograms of DHMXAN nanospheres (A) and
nanocapsules (B).
Table V shows encapsulation parameters, mean particle size,
polydispersity, and zeta potential of PLGA nanoparticle formula-
tions. Nanospheres and nanocapsules showed mean diameters
around 140 nm and 265 nm, respectively, and zeta potential
values > –40 mV. Encapsulation efficiency is the percentage of
drug incorporated in nanoparticles with respect to the initial
amount of drug used. Higher encapsulation efficiency was
observed for nanocapsules (80.4%) than for nanospheres (39.4%).
This result is in accordance with the data we have obtained in a
previouswork for other xanthonic derivatives (27). Several factors
influence the amount of drug associated with nanosystems, such
as drug affinity for the polymer, type of polymer, type of oil, and
drug solubility in the oily core (28–30). Our results suggest that
the encapsulated xanthonic compound, which presents a
lipophilic character (log P value = 2.6, calculated using the
CSLogP™ program of Chemsilico), has low affinity for the
polymer and is soluble in the oily core of nanocapsules.
Conclusions
A simple isocratic reversed-phase HPLC method was devel-
oped for the determination of DHMXAN in PLGA nanosphere
and nanocapsule formulations, which was entrapped for the first
time in this type of nanocarriers. The method was validated
according to ICH guidelines and USP 29 for its specificity, lin-
earity, accuracy, and precision. Obtained results showed that the
proposed method is specific, linear, accurate, and precise within
the established range.
No degradation of the compoundwas found upon nanoparticle
preparation by the adopted solvent displacement methods and
high encapsulation efficiencies were obtained for nanocapsule
formulations. Results clearly demonstrate the suitability of the
selected methods for incorporating DHMXAN in PLGA nanopar-
ticles.
The developed and validated HPLC method was successfully
applied to the quantification of DHMXAN content in nanopar-
ticle formulations, affording an important tool for the quality
control of finished products. Obtained nanosystems are under
study in vitro on a tumour cell line.
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